Literature DB >> 23358980

Pulmonary fibrosis after pegylated liposomal Doxorubicin in a patient with uterine papillary serous carcinoma.

Nicole S Nevadunsky1, Chinyere Mbagwu, Nina Mizrahi, Elizabeth Burton, Gary L Goldberg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23358980      PMCID： PMC4878101          DOI： 10.1200/JCO.2012.44.5767

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  10 in total

1.  International guidelines for the selection of lung transplant candidates: 2006 update--a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation.

Authors:  Jonathan B Orens; Marc Estenne; Selim Arcasoy; John V Conte; Paul Corris; Jim J Egan; Thomas Egan; Shaf Keshavjee; Christiane Knoop; Robert Kotloff; Fernando J Martinez; Steven Nathan; Scott Palmer; Alec Patterson; Lianne Singer; Gregory Snell; Sean Studer; J L Vachiery; Allan R Glanville
Journal:  J Heart Lung Transplant       Date:  2006-07       Impact factor: 10.247

2.  The effect of adjuvant chemotherapy versus whole abdominopelvic radiation on the survival of patients with advanced stage uterine papillary serous carcinoma.

Authors:  Chad A Hamilton; Michael K Cheung; Kathryn Osann; Bonnie Balzer; Michael L Berman; Amreen Husain; Nelson N Teng; Daniel S Kapp; John K Chan
Journal:  Gynecol Oncol       Date:  2006-06-21       Impact factor: 5.482

3.  The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study.

Authors:  D Scott McMeekin; Virginia L Filiaci; J Tate Thigpen; Holly H Gallion; Gini F Fleming; William H Rodgers
Journal:  Gynecol Oncol       Date:  2007-07       Impact factor: 5.482

4.  Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours.

Authors:  J M O'Sullivan; R A Huddart; A R Norman; J Nicholls; D P Dearnaley; A Horwich
Journal:  Ann Oncol       Date:  2003-01       Impact factor: 32.976

5.  An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.

Authors:  Ganesh Raghu; Harold R Collard; Jim J Egan; Fernando J Martinez; Juergen Behr; Kevin K Brown; Thomas V Colby; Jean-François Cordier; Kevin R Flaherty; Joseph A Lasky; David A Lynch; Jay H Ryu; Jeffrey J Swigris; Athol U Wells; Julio Ancochea; Demosthenes Bouros; Carlos Carvalho; Ulrich Costabel; Masahito Ebina; David M Hansell; Takeshi Johkoh; Dong Soon Kim; Talmadge E King; Yasuhiro Kondoh; Jeffrey Myers; Nestor L Müller; Andrew G Nicholson; Luca Richeldi; Moisés Selman; Rosalind F Dudden; Barbara S Griss; Shandra L Protzko; Holger J Schünemann
Journal:  Am J Respir Crit Care Med       Date:  2011-03-15       Impact factor: 21.405

Review 6.  Interstitial lung diseases of unknown cause. Disorders characterized by chronic inflammation of the lower respiratory tract (first of two parts).

Authors:  R G Crystal; P B Bitterman; S I Rennard; A J Hance; B A Keogh
Journal:  N Engl J Med       Date:  1984-01-19       Impact factor: 91.245

7.  Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a Gynecologic Oncology Group study.

Authors:  Franco M Muggia; John A Blessing; Joel Sorosky; Gary C Reid
Journal:  J Clin Oncol       Date:  2002-05-01       Impact factor: 44.544

Review 8.  Idiopathic pulmonary fibrosis.

Authors:  T J Gross; G W Hunninghake
Journal:  N Engl J Med       Date:  2001-08-16       Impact factor: 91.245

9.  Racial disparities for uterine corpus tumors: changes in clinical characteristics and treatment over time.

Authors:  Jason D Wright; Jessica Fiorelli; Peter B Schiff; William M Burke; Amanda L Kansler; Carmel J Cohen; Thomas J Herzog
Journal:  Cancer       Date:  2009-03-15       Impact factor: 6.860

10.  Platinum/taxane-based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma.

Authors:  Amanda Nickles Fader; Richard D Drake; David M O'Malley; Heidi E Gibbons; Warner K Huh; Laura J Havrilesky; Paola A Gehrig; Erin Tuller; Allison E Axtell; Kristine M Zanotti
Journal:  Cancer       Date:  2009-05-15       Impact factor: 6.860
  10 in total
  5 in total

Review 1.  Doxorubicin-Induced Cardiomyopathy in Children.

Authors:  Trevi R Mancilla; Brian Iskra; Gregory J Aune
Journal:  Compr Physiol       Date:  2019-06-12       Impact factor: 9.090

Review 2.  PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer.

Authors:  Felicia Roncolato; Kristina Lindemann; Melina L Willson; Julie Martyn; Linda Mileshkin
Journal:  Cochrane Database Syst Rev       Date:  2019-10-07

3.  Inhalable PEGylated Phospholipid Nanocarriers and PEGylated Therapeutics for Respiratory Delivery as Aerosolized Colloidal Dispersions and Dry Powder Inhalers.

Authors:  Priya Muralidharan; Evan Mallory; Monica Malapit; Don Hayes; Heidi M Mansour
Journal:  Pharmaceutics       Date:  2014-06-20       Impact factor: 6.321

4.  Pulmonary Fibrosis after Pegylated Liposomal Doxorubicin in Elderly Patient with Cutaneous Angiosarcoma.

Authors:  Marco Mazzotta; Raffaele Giusti; Daniela Iacono; Salvatore Lauro; Paolo Marchetti
Journal:  Case Rep Oncol Med       Date:  2016-01-20

5.  Serpine 1 induces alveolar type II cell senescence through activating p53-p21-Rb pathway in fibrotic lung disease.

Authors:  Chunsun Jiang; Gang Liu; Tracy Luckhardt; Veena Antony; Yong Zhou; A Brent Carter; Victor J Thannickal; Rui-Ming Liu
Journal:  Aging Cell       Date:  2017-07-19       Impact factor: 9.304
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.